dc.contributor.author | Løland, Kjetil Halvorsen | en_US |
dc.contributor.author | Bleie, Øyvind | en_US |
dc.contributor.author | Strand, Elin | en_US |
dc.contributor.author | Ueland, Per Magne | en_US |
dc.contributor.author | Nordrehaug, Jan Erik | en_US |
dc.contributor.author | Garcia-Garcia, Hector M. | en_US |
dc.contributor.author | Serruys, Patrick W. | en_US |
dc.contributor.author | Nygård, Ottar | en_US |
dc.date.accessioned | 2014-06-19T09:46:35Z | |
dc.date.available | 2014-06-19T09:46:35Z | |
dc.date.issued | 2013-07-25 | eng |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | https://hdl.handle.net/1956/7989 | |
dc.description.abstract | Background: Virtual Histology Intravascular Ultrasound (VH–IVUS) may be used to detect early signs of unstable coronary artery disease. Monocyte Chemoattractant Protein-1 (MCP-1) is linked with coronary atherosclerosis and plaque instability and could potentially be modified by folic acid treatment. Methods: In a randomized, prospective study, 102 patients with stable angina pectoris (SAP) received percutaneous coronary intervention and established medical treatment as well as either homocysteine-lowering folic acid/vitamin B12 (±B6) or placebo (±B6) for 1 year before VH–IVUS was performed. The presence of VH-Thin-Cap Fibroatheroma (VH-TCFA) in non-intervened coronary vessels was registered and serum levels of MCP-1 were measured. The patients were subsequently followed for incident myocardial infarction (MI). Results: Patients treated with folic acid/vitamin B12 had a geometric mean (SD) MCP-1 level of 79.95 (1.49) versus 86.00 (1.43) pg/mL for patients receiving placebo (p-value 0.34). VH-TCFA lesions were present in 7.8% of patients and did not differ between intervention arms (p-value 0.47). Serum levels of MCP-1 were 1.46 (95% CI 1.12 to 1.92) times higher in patients with VH-TCFA lesions than in those without (p-value 0.005). Afterwards, patients were followed for median 2.1 years and 3.8% experienced a myocardial infarction (MI), which in post-hoc Cox regression analyses was independently predicted by both MCP-1 (P-value 0.006) and VH-TCFA (p-value 0.01). Conclusions: In patients with SAP receiving established medical treatment, folic acid supplementation is not associated with either presence of VH-TCFA or levels of MCP-1. MCP-1 is however associated with VH-TCFA, a finding corroborated by increased risk for future MI. | en_US |
dc.language.iso | eng | eng |
dc.publisher | Public Library of Science | eng |
dc.relation.ispartof | <a href="http://hdl.handle.net/1956/7990" target="blank">Folic acid supplementation and biomarkers of progression of sub-clinical coronary atherosclerosis in patients with stable angina pectoris</a> | eng |
dc.rights | Attribution CC BY | eng |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/ | eng |
dc.title | Effect of Folic Acid Supplementation on Levels of Circulating Monocyte Chemoattractant Protein-1 and the Presence of Intravascular Ultrasound Derived Virtual Histology Thin-Cap Fibroatheromas in Patients with Stable Angina Pectoris | en_US |
dc.type | Peer reviewed | |
dc.type | Journal article | |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2013 Løland et al. | |
dc.source.articlenumber | e70101 | |
dc.identifier.doi | https://doi.org/10.1371/journal.pone.0070101 | |
dc.identifier.cristin | 1059424 | |
dc.source.journal | PLoS ONE | |
dc.source.40 | 8 | |
dc.source.14 | 7 | |